Theresa Link on Muck Rack

Theresa Link

As seen in: Nature, JAMA Oncology, ONCOLOGY journal
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Theresa

Contact Theresa, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Theresa Link | Authors | CancerNetwork

|
By Theresa Link
| ONCOLOGY journal Verified
259 Prospect Plains Rd, Bldg H Cranbury, NJ 08512
Open in Who Shared View Duplicates (366) Issue with article?

Tumor mutations predict HER2-targeted therapy resistance in primary HER2-positive breast cancer

|
By Marion van Mackelenbergh, Nicole Pfarr, Karsten Weber, Michael Untch, Christine Solbach, Andreas Schneeweiss, Paul Jank, Jens Blohmer, Sabine Schmatloch, Annika Lehmann, Claus Hanusch, Theresa Link, Christine Sers, Vesna Bjelic-Radisic, Michael Hummel, Jens Huober, Wolfgang Schmitt, Bahriye Aktas, Kerstin Rhiem, Mattea Reinisch, Valentina Nekljudova, Carsten Denkert, Sibylle Loibl, Denise Treue
| Nature Verified
Abstract The presented study investigated the relevance of mutations in 17 cancer genes and response to neoadjuvant chemotherapy in two clinical cohorts of HER2+ breast cancer. 364 samples from HER2+ tumors of the neoadjuvant studies GeparTrio (no anti-HER2 treatment, n = 71) and GeparSepto (dual HER2 blockade and randomization for paclitaxel vs. nab-paclitaxel, n = 293) were analyzed by targeted next generation sequencing of hot spot regions of 17 genes.
Open in Who Shared Issue with article?

PARP inhibition with olaparib and talazoparib for HER2-negative advanced breast cancer—Results from the prospective PRAEGNANT registry

|
By Andreas Hartkopf, Nelson John, Philipp A. Ziegler, Lothar Häberle, Chloë Goossens, Jan-Philipp Cieslik, Dominik Dannehl, Thomas Deutsch, Moritz Dimpfl, Melitta B. Köpke, Annika Krückel, Theresa Link, Annika Müller, Kristin Reinhardt, Jonas Roth, Henning Schäffler, Nikolas Tauber, Christian M. Tegeler, Maggie Banys-Paluchowski, Achim Rody, Sara Brucker, Nina Ditsch, Johannes Ettl, Tanja Fehm, Peyman Hadji, Alexander Ochoa Hein, Wolfgang Janni, Hans-Christian Kolberg, Diana Lüftner, Michael Lux, Volkmar Müller, Florin-Andrei Taran, Hans Tesch, Diethelm Wallwiener, Frederik Marmé, Stephan Seitz, Laura Michel, Markus Wallwiener, Andreas Schneeweiss, Christian Maurer, Manuel Hörner, Sabrina Uhrig, Niklas Amann, Lara M. Tretschock, Max Ehlert, Kathleen Eichstädt, Alexander Englisch, Lea Sych, Catharina Wichmann, Henriette Princk, Erik Belleville
| Nature Verified
Abstract Germline BRCA1 and BRCA2 mutations enable targeted therapies in human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer (ABC). The two poly (adenosine diphosphate-ribose) polymerase (PARP) inhibitors olaparib and talazoparib were introduced into clinical practice in 2018. Limited evidence about their routine clinical use highlights the importance of this analysis.
Open in Who Shared Issue with article?
See all 5 articles
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified